QuanMedAI
Menu

At-Home Cancer Genetic Tests Compared: Clinical-Grade vs Consumer, Genes Covered & Pricing

Not all cancer genetic tests are equal — clinical NGS panels and consumer array tests offer radically different coverage. Here is the complete 2026 comparison.

By Dr. Elena Marsh, Health Technology Correspondent

Published: November 18, 2026 · 10 min read

Quick Answer

Clinical-grade hereditary cancer panels (Myriad MyRisk 48 genes, Invitae 84 genes, Color 30 genes) use full NGS sequencing in CLIA-certified labs and are clinically equivalent to hospital testing. Consumer tests (23andMe) cover only 3 BRCA variants, missing 97%+ of clinically significant BRCA mutations. For actionable hereditary cancer risk information, clinical-grade testing is essential. Consumer tests are not adequate substitutes for clinical BRCA screening.

Clinical-Grade vs Consumer: The Critical Distinction

The at-home cancer genetic testing market divides into two fundamentally different categories that are often conflated in consumer comparisons. Clinical-grade hereditary cancer tests use next-generation sequencing (NGS) — the same technology used in hospital genetic laboratories — to read and analyse the full sequence of relevant cancer-associated genes. Consumer array-based tests use genotyping chips that only check for specific, predetermined variants chosen during chip design.

This distinction has profound clinical implications. BRCA1 alone has over 1,800 pathogenic variants documented in clinical databases. 23andMe's health test covers three of them — the three Ashkenazi Jewish founder variants that are prevalent in one specific population. A negative result from 23andMe's BRCA test means those three specific variants were not found. It says nothing about the other 1,797+ pathogenic BRCA1 variants, nor anything about BRCA2, nor any of the other 20+ clinically actionable hereditary cancer genes.

TestTechnologyGenes coveredCLIA certifiedPrice
Myriad MyRiskNGS + Sanger confirm48 genesYes (CAP)$250 w/ ins; ~$4,000 self-pay
Invitae (84 gene)NGS84 genesYes (CAP)$250 self-pay
Color GenomicsNGS30 genesYes (CAP)$249–$299 direct
Ambry GeneticsNGS + MLPA42+ genesYes (CAP)$250 w/ ins
23andMe HealthGenotyping array3 BRCA variants onlyYes (limited)$229 (full kit)

What Genes Matter Most for Hereditary Cancer Risk?

The clinical significance of a hereditary cancer panel is determined primarily by the number of clinically actionable genes it covers — genes for which a positive result changes medical management. The core actionable genes in 2026 guidelines include:

  • BRCA1/BRCA2 — Lifetime breast cancer risk 50–70%; ovarian 15–45%; pancreatic 2–7%; prostate (BRCA2) 20–40%
  • Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) — Colorectal cancer risk 20–80% lifetime; endometrial 15–50%
  • PALB2 — Breast cancer risk 35–60% lifetime; pancreatic cancer 2–5×
  • ATM — Breast cancer risk 15–25% lifetime; pancreatic and prostate elevated
  • CDH1 — Hereditary diffuse gastric cancer; prophylactic gastrectomy recommended for pathogenic carriers
  • TP53 — Li-Fraumeni syndrome; very broad cancer risk elevation across multiple types

A clinical-grade 48–84 gene panel covers all of these plus moderate-penetrance genes (CHEK2, RAD51C/D, BARD1) where risk estimates are still being refined. Consumer tests with limited variant coverage miss the majority of clinically significant findings across all these genes.

Key Sources

  • NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (2026)
  • BRCA false negatives from 23andMe — JAMA Oncology (2022)
  • Invitae clinical validation data (2026 product disclosure)
  • Color Genomics direct-to-consumer hereditary cancer testing outcomes — Genetics in Medicine (2025)

Frequently Asked Questions

Deep Dive

Polygenic Risk Scores: What Your DNA Predicts

Our comprehensive guide covers the science, protocols, and tools in detail — with FAQs answered by our research team.

Read the Full Guide →

© 2026 QuanMed - All rights reserved